JP6785804B2 - Ｂ細胞悪性腫瘍を治療するための組合せ療法 - Google Patents

Ｂ細胞悪性腫瘍を治療するための組合せ療法 Download PDF

Info

Publication number
JP6785804B2
JP6785804B2 JP2017566806A JP2017566806A JP6785804B2 JP 6785804 B2 JP6785804 B2 JP 6785804B2 JP 2017566806 A JP2017566806 A JP 2017566806A JP 2017566806 A JP2017566806 A JP 2017566806A JP 6785804 B2 JP6785804 B2 JP 6785804B2
Authority
JP
Japan
Prior art keywords
compound
idelalisib
cell
combination
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017566806A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519300A (ja
JP2018519300A5 (https=
Inventor
コリンズ，ヘレン
パオロ，ジュリー ディ
パオロ，ジュリー ディ
キーガン，キャシー
龍平 小崎
龍平 小崎
メドウズ，サラ
ネルソン，カラ
クエバ，クリストフ
ラマナサン，スリニバサン
タンハイマー，ステイシー
トゥマス，ダニエル
とも子 康廣
とも子 康廣
敏男 吉澤
敏男 吉澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of JP2018519300A publication Critical patent/JP2018519300A/ja
Publication of JP2018519300A5 publication Critical patent/JP2018519300A5/ja
Application granted granted Critical
Publication of JP6785804B2 publication Critical patent/JP6785804B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017566806A 2015-06-23 2016-06-22 Ｂ細胞悪性腫瘍を治療するための組合せ療法 Expired - Fee Related JP6785804B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562183699P 2015-06-23 2015-06-23
US62/183,699 2015-06-23
US201562200610P 2015-08-03 2015-08-03
US62/200,610 2015-08-03
US201562263454P 2015-12-04 2015-12-04
US62/263,454 2015-12-04
PCT/US2016/038763 WO2016209961A1 (en) 2015-06-23 2016-06-22 Combination therapies for treating b-cell malignancies

Publications (3)

Publication Number Publication Date
JP2018519300A JP2018519300A (ja) 2018-07-19
JP2018519300A5 JP2018519300A5 (https=) 2019-06-06
JP6785804B2 true JP6785804B2 (ja) 2020-11-18

Family

ID=56497846

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017566806A Expired - Fee Related JP6785804B2 (ja) 2015-06-23 2016-06-22 Ｂ細胞悪性腫瘍を治療するための組合せ療法

Country Status (5)

Country Link
US (1) US20180353512A1 (https=)
EP (1) EP3313405A1 (https=)
JP (1) JP6785804B2 (https=)
TW (1) TW201713344A (https=)
WO (1) WO2016209961A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180207164A1 (en) * 2015-08-03 2018-07-26 Gilead Sciences, Inc. Combination therapies for treating cancers
CA3101323A1 (en) * 2018-06-01 2019-12-05 Incyte Corporation Dosing regimen for the treatment of pi3k related disorders
CA3158321A1 (en) * 2019-11-04 2021-05-14 Astrazeneca Ab Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies
KR20210115375A (ko) * 2020-03-12 2021-09-27 보령제약 주식회사 Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물
WO2023030437A1 (zh) * 2021-09-01 2023-03-09 江苏恒瑞医药股份有限公司 一种pi3k抑制剂与btk抑制剂在制备治疗淋巴瘤的药物中的用途
CN114831991B (zh) * 2022-06-10 2024-02-06 陕西科技大学 Gsk2334470用于制备抗真菌药物及其增效剂的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4943593A (en) 1988-02-25 1990-07-24 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5059714A (en) 1988-02-25 1991-10-22 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5252608A (en) 1988-02-25 1993-10-12 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5182297A (en) 1988-02-25 1993-01-26 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5120764A (en) 1988-11-01 1992-06-09 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US4997854A (en) 1989-08-25 1991-03-05 Trustees Of Boston University Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamine analogue substrates
FR2828206B1 (fr) 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
BR112012030711B1 (pt) * 2010-05-31 2020-10-13 Ono Pharmaceutical Co. Ltd derivado de purinona
DK2786996T3 (en) * 2011-11-29 2016-12-19 Ono Pharmaceutical Co Hydrochloride PURINONDERIVAT
SG11201509842SA (en) * 2013-05-30 2015-12-30 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
EA201691169A1 (ru) * 2013-12-05 2016-09-30 Асерта Фарма Б.В. Терапевтическая комбинация ингибитора pi3k и ингибитора btk
MA40596B1 (fr) * 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2

Also Published As

Publication number Publication date
JP2018519300A (ja) 2018-07-19
WO2016209961A1 (en) 2016-12-29
EP3313405A1 (en) 2018-05-02
US20180353512A1 (en) 2018-12-13
TW201713344A (zh) 2017-04-16

Similar Documents

Publication Publication Date Title
US20240325398A1 (en) Combination therapies
JP2021143182A (ja) 癌を治療するためのｂｔｋ阻害剤とチェックポイント阻害剤との組合せ
JP6963146B1 (ja) 癌を治療するためのｋｒａｓ阻害剤の投与
JP6785804B2 (ja) Ｂ細胞悪性腫瘍を治療するための組合せ療法
US20240293415A1 (en) Combination therapies
TW201639573A (zh) 有關治療癌症之合併治療
TW201609105A (zh) 治療骨髓增生失調之療法
TW201620519A (zh) 治療癌症之療法
AU2013302617A1 (en) Combination therapies for treating cancer
MX2013014151A (es) Metodos para tratar el mesotelioma con un compuesto inhibidor de la pi3k.
JP2021001237A (ja) がん処置のための組み合わせ療法
JP7547360B2 (ja) Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法
US20260116962A1 (en) Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190423

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190423

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200528

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200929

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201027

R150 Certificate of patent or registration of utility model

Ref document number: 6785804

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees